Attached files
| file | filename |
|---|---|
| EX-99.1 - Altimmune, Inc. | v175796_ex99-1.htm |
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
DC 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of
Report (Date of earliest event reported): February 22,
2010
PHARMATHENE,
INC.
(Exact
name of registrant as specified in its charter)
|
Delaware
|
001-32587
|
20-2726770
|
||
|
(State
or other jurisdiction
of
incorporation)
|
(Commission
File
Number)
|
(IRS
Employer
Identification
No.)
|
|
One Park Place, Suite 450, Annapolis,
Maryland
|
21401
|
|
|
(Address
of principal executive offices)
|
(Zip
Code)
|
Registrant’s
telephone number including area code: (410) 269-2600
(Former
name or former address, if changed since last report)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
|
¨
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|
|
¨
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
¨
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
|
¨
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
Item
1.01.
Entry into a Material
Definitive Agreement
On
February 22, 2010, PharmAthene, Inc., a Delaware corporation
(“PharmAthene”), amended its existing research and development contract with the
U.S. Department of Health and Human Services (HHS), operating through the
Biomedical Advanced Research and Development Authority (BARDA)
(HHSO100200900103C), to support the continued advanced development of
SparVax™, a second generation recombinant protective antigen (rPA) anthrax
vaccine targeted for future procurement in the U.S. Strategic National Stockpile
(SNS).
The
contract modification, which is effective February 22, 2010 and extends through
December 31, 2012, provides for additional advanced development funding for
SparVax™. During the base period of performance under the contract
modification, i.e., through December 31, 2012, PharmAthene could receive
payments of up to approximately $61 million on a
cost-reimbursement-plus-fixed-fee basis, assuming that all milestones are
achieved.
Under the
contract modification, the government, at its sole discretion, may exercise
three contract options during the base period of
performance. Assuming that the government exercises all three
options, PharmAthene could receive up to an additional $17 million under the
contract modification.
As disclosed in PharmAthene’s previous
SEC filings, on September 28, 2007, NIAID and BARDA awarded to PharmAthene a
$13.9 million contract for the advanced development of Valortim® as an
anti-toxin therapeutic to treat inhalation anthrax
infection.
Attached
hereto as Exhibit 99.1 is a press release from February 23, 2010, in which
PharmAthene announced the contract modification.
Item 9.01 Financial Statements and
Exhibits
(d) Exhibits
|
No.
|
Description
|
|
|
99.1
|
Press
release, dated February 23, 2010, issued by the
Company.
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
PHARMATHENE,
INC.
(Registrant)
|
||
|
Date: February
26, 2010
|
By:
|
/s/ Charles A. Reinhart III |
|
Charles
A. Reinhart III
Senior
Vice President and Chief Financial
Officer
|
||